COMPANY PROFILE HIGHLIGHTS

• TrialTrove's top leadership includes Stephen A. Carter (CEO of Informa PLC), Charlie McCurdy (CEO of Informa Markets), and Andrew Mullins (CEO of Informa Connects).
•  Sarah Cottrell (CTO of Informa) and Simon Hollins (Chief Information Officer of Informa) are some top technical employees of the company.
• Informa acquired UBM Plc in January 2018 for £3.9 billion. The company also bought Dove medical press in September 2017 for an undisclosed amount, Boatquest in March 2017 for $106 million and Show Management for an undisclosed amount in March 2017.
• TrialTrove present in the United States, United Kingdom, Australia, Japan, and Europe.
• Trialtrove offers clinical trial data and intelligence.

RESEARCH STRATEGY

Trial Trove

Licensed Technologies

• The licensed technology the company uses: RxScorecard 

Key Customers

• The company has around 3000 clients, which include key clients such as TFS International, HalozymeTherapeutics, UPMC Healthplan, Harvard Pilgrim Healthcare, and GlaxoSmithKline.

Types of Data Held

• Trial benchmarks and metrics, enrollment success, study timelines, targeted patient populations, and geographic distribution.

Amount of Data Held/# of Patients

•  248,000 

Data Storage Methods

• The next generation Sitetrove and Trialtrove enable the client's data to be integrated and stored directly into their workflow tools and Citeline partners’ solutions.

Research Strategy:

TYPES OF MEDICAL CENTERS

• Pharmaceutical companies
• Contract research organizations
• Consultancies
• Marketing agencies
• Medtech sector

AGREEMENTS WITH MEDICAL CENTERS

• As per Informa's privacy policy associated with its entire suite of Citeline products, of which Trialtrove is a part, it collects contact details, background information, usernames and passwords, payment information, location information, and others. Cinteline uses this data in the following main contexts:
• As an existing or potential buyer of their products and services.
• As an existing or potential user of their products and services.
• As a person of interest featured within their products and services.
• If collecting or storing "sensitive personal data, such as information relating to health, beliefs or political affiliation", they typically request explicit consent.

TWO MAIN COMPETITORS

•  Category 1: Karmadata designs, develops, builds and provides clinical trial database and decision support applications for the healthcare industry.

•  Category 2: BioCentury Publications provide information, analysis, and data for biotechnology and pharmaceutical companies.

COMPETITORS IN EUROPE/ASIA

•  Category 1: GlobalData provides coverage of ~250,000 trials (covering rare and niche diseases) — includes observational studies, in addition to interventional and expanded access.

•  Category 2: Evaluate is a provider of commercial intelligence, insights and consensus forecasts for the pharmaceutical industry.

TECHNICAL INFORMATION ON DATA

• Informa’s trials and drugs APIs enable users to search or stream information directly from "Citeline’s R&D Intelligence databases into their own systems and embed Informa’s quality data sets directly into their own organization’s data and workflows, minimizing duplicated effort and time spent acquiring and manipulating data".

• Saama Technologies, Inc. partnered with Citeline to provide "cutting-edge artificial intelligence, machine learning and deep learning solutions with Citeline’s new application programming interfaces (APIs) to link global clinical data with real-world data".

• MIT Laboratory for Financial Engineering (LFE) and Informa Pharma Intelligence partner on Project ALPHA (Analytics for Life-sciences Professionals and Healthcare Advocates), an initiative to provide timely and more accurate estimates of the risks and rewards of clinical trials to the entire biopharma ecosystem. Clinical success rate metrics are the first set of analytics to be included as part of Project ALPHA based on algorithms developed by MIT researchers.

Company profile Highlights

• Get Real Health's top leadership includes: Robin Wiener (CEO, president and founding partner); Mark Heaney (chief strategist and founding partner); and Matt Soska (CFO).
• Get Real Health's top technical team comprises: Jason Harmon (founding partner and CTO) and Rajesh C.K.R. (managing partner — Indian developers operations).
• Get Real Health was acquired by CPSI on April 24, 2019, at a cost of $11 million and an additional earn-out of up to $14 million on Get Real Health's 2019 EBITDA.
• Get Real Health is present in United States, United Kingdom, Netherlands, Sweden, Australia, Canada, Italy, Qatar, United Arab Emirates, Egypt, and other Middle East and Africa (MESA) countries.
• Get Real Health's products include: InstaPHR, CHBase, Ellie, and Lydia.

Research Strategy:

• Sweden's eHealth Agency,
• MedStar Health,
• New-York Presbyterian.

KEY FINDINGS

• The company holds records/provides data for hospitals and HIEs; non-profit organizations; research, pharma, and biotech centers; employees of a workplace; health insurance companies; health ministries and government organizations; and public and private healthcare organizations.
• Get Real Health has an End Users License Agreement for Lydia™, a health management tool. The agreement oversees the license and use of the products.
• A competitor in the category of companies that use data to improve patient identification is Doxy.me, because it has a similar customer base (clinics, hospitals, health systems, and professional organizations) and provides solutions with similar goals (such as real-time healthcare for remote patients and patient engagement by improving patient outcome and reducing readmission). It was originally built for clinical studies surrounding prenatal care research.
• A competitor in the same category in Europe is Orion Health that provides similar solutions as Get Real Health to a similar customer base in the same region (for example, Europe and Middle Eastern countries). The company provides its services to pharmaceutical companies and helps them access patient data that can be used in research and development for patient identification and investments.
• A competitor in the category of companies that have secured access to large amounts of healthcare data is Playback Health because it has similar goals as Get Real Health (enhance customer engagement for better health outcomes). Playback Health provides patient engagement solutions by using video recording technology which creates and stores content (accessible via mobile phones) that can be used to inform and educate patients about their diagnosis, treatment, and discharge. The company has a large amount of healthcare data from physician visits, emergency room visits, hospital outpatient visits, and hospital admissions.
• A competitor in the same category in Europe is Samedi because it provides similar solutions (patient engagement) and operates in similar regions (Germany, Sweden, and Austria). The company has a significant quantity of secured data that can be accessed with patient consent from digital patient files and records.
• Two of Get Real Health's core technologies are CHBase and InstantPHR®.

YEAR FOUNDED

• The company was founded in the year 2015.

FUNDING HISTORY

• In April 2016, they received round one of Incubator/Accelerator funding.
• In September 2016, they received round two of Incubator/Accelerator funding.
• In February 2018, they received a corporate venture funding.

NAMES AND POSITIONS OF THE TOP 4 PERSONNEL OF THE COMPANY

Wout Brusselaers

• Wout is the Chief Executive Officer and Co-founder of Deep 6
• He started his career as a diplomat in the Middle East and later joined a global management consulting firm, McKinsey & Company.
• Then, he founded an extreme sports adventure company in Singapore.
• In 2015, Wout co-founded Deep 6 AI.  

Andrew Hall

• Andrew is the Chief Technology Officer at Deep 6.
• He has about 25 years experience in software technology.
• He has a proven track record of incorporating new technology to build innovative products successfully.
• He was formerly the "Vice President of Engineering at Instant.ly and Director of Engineering for Securant Technologies."
• "Andrew is responsible for leading the development of Deep 6 AIs' scalable application and security infrastructure. "

Doug Cassidy

• Doug is the Vice President, Clinical and Academic Partnerships at Deep 6.
• He studied Biomedical Engineering and Computer Science at Wright State University.
• He also has a degree in Global Health from Harvard University.
• Doug has over 20 years of experience exclusively in the healthcare IT Space.
• He was formerly a senior sales manager for industry leaders such as GE Healthcare, Orion Health, and Hyland OnBase.
• Before venturing into sales, he worked in other areas like clinical informatics, software development, data architecture, neural network design, and artificial intelligence.

Eric Gildenhuys

• Eric is the Vice President, Business Development at Deep 6.
• He began his career by co-founding and selling a software company to Optio Software.
• Eric has 25 years experience in helping companies improve their revenue streams.
• "For the past 14 years, Eric has been helping software and professional services firms such as PwC all over the world in shifting the paradigm of their business development culture, resulting in new contracts worth $100+ million. "

Licensed Technologies

•  Deep 6 AI Software 
•  Deep 6 AI’s Cohort Builder

Key Customers

•  Cedars-Sinai Medical Center 
•  TD2
•  PCORI (Patient-Centered Outcomes Research Institute)

Types of Data Held

•  Clinical data 
•  Clinical trial data 
•  Patient data and medical records
•  Patient population data 

Amount of Data Held BY NUMBER of Patients

• The company has 2.2 million patient records.

Data Storage Methods

• The company uses computers/servers as data storage and they are kept in a secure environment.

A) Types of Medical Centers

• The different types of medical centers and people that the company serves/helps include: 

B) Agreements with Medical Centers

• In 2017, Deep 6 AI signed a formal agreement with Translational Drug Development (TD2) to work together in the fields of oncology and fibrosis to rapidly match eligible patients with appropriate clinical trials.
• As per the partnership agreement, TD2, which is an oncology development organization, was granted access to Deep 6's artificial intelligence system.
• The agreement provided TD2 access to all structured and unstructured clinical data, including physician notes and pathology and genomic reports.
• The agreement also entailed the establishment of a network of the top Phase 1 and 2 sites in oncology clinical trials to expand the industry access to patient electronic data.

C) Two Main Competitors

• Antidote was founded in 2010 and is headquartered in London, England with offices in New York, NY and Carmel, Indiana.
• The company is a main competitor of Deep 6 AI because it also uses machine learning to connect patients to medical research studies through its clinical trial matching platform.
• The company's 'Antidote Match' search engine scours through thousands of open trials using algorithms trained on different patient eligibility criteria for clinical trials in order to recruit apt patients for the various clinical trials.
• The company has expanded its platform access to health organizations by allowing its match search engine to be embedded into the websites of its partners
• As a mark of success, Antidote was able to successful recruit 8,000 out of 10,000 participants required for a clinical trial relating to Alzheimer’s disease in less than 2 months and its referrals were seven times more likely to complete the required follow-up than referrals from other sources.

• Trials AI was founded in 2015 and is based in San Diego, California.
• The company is a main competitor of Deep 6 AI because it leverages natural language processing (NLP) to help researchers manage their clinical trial workflows more efficiently.
• The company has access to large amount of healthcare data in the form of billions of data points from past clinical trials, medical journals, EHR records, and real-world sources to identify risk factors and provide recommendations for clinical trial optimization through the use of its algorithmic driven cloud-based 'Study Optimizer platform'.
• As a mark of success, Trials AI helped the Moores Cancer Center at UC San Diego Health shorten its study timelines by nearly 33% and reduce data errors by 20%.

D) Competitors In Europe/Asia

• Clinithink was founded in 2009 and is based in London, UK.
• The company is a main competitor of Deep 6 AI, as it also uses AI to help various medical centers recruit apt patients for their clinical trials.
• The company's patent-pending clinical language indexing software (CLiX) uses natural language processing (NLP) to construct coded output from physicians’ notes using industry data standards (ICD-9, ICD-10, and SNOMED CT) to identify apt recruits for the various clinical trials.

• Stuntec was founded in 1999 and is based in New Delhi, India.
• The company is a main competitor of Deep 6 AI because it also uses large amount of healthcare data and predictive models to drive insights for its clients.
• Stuntec India provides access to a large amount of healthcare data such as electronic medical records (EMR), electronic health records (EHR), medical imaging databases, health insurance claims. It leverages the latest data mining tools to extract, analyze and convert data into useful information for its clients.
• Similar to Deep Six AI, some of the company's clients includes medical centers such as hospitals, clinics and physicians.

E) Technical Information On Data

• Deep Six leverages client data along with natural language processing, medical ontologies, machine learning and artificial intelligence to process medical records and generate insightful clinical trial data.
• Deep Six's software analyzes structured data, such as ICD-10 codes, and unstructured clinical data, including doctor’s notes, pathology reports, operating notes and other important medical data in free-text form that cannot be searched easily.
• The company's data architecture consists of 3 steps namely extract, analyze and connect.
• In the 'Extract' phase, the clinical data is distilled into key elements such as symptoms, diagnoses, treatments, test results, genomics, and socio-economics while masking protected health information.
• In the 'Analyze' phase, the clinical data points extracted from the medical record in the last phase are aggregated into a multi-dimensional clinical profile with unified patient graphs that contain all the information needed to match complex clinical trial criteria.
• In the 'Connect' phase, researchers, analysts and doctors can use the multidimensional profiles to find and compare patients, cohorts and populations data.
• The Company has a patented software called 'Cohort Builder 3.1' that helps its clients find patients who better match trial criteria in a fraction of the time.